TapewireFind a company

person · Reporting owner

WAGENHEIM PHILIP

Disclosed activity across 2 companies

Tapewire entity
22845
SEC CIK
0001405684

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Immunome Inc.IMNM · Entity 4219DirectorJune 10, 2026June 12, 2026
Swarmer, IncSWMR · Entity 5442DirectorOctober 01, 2026October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunome Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09Direct9,897 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897

F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Swarmer, Inc

Report date October 01, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.38 · Expires 2036-10-01Direct6,428 Reported balance After 2026-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-10-01 · Grant · Acquired 6,428 · Balance 6,428

F1: The shares underlying this option shall vest in full on the earlier of (i) the one-year anniversary of the grant date and (ii) the Issuer's 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full on the earlier of (i) the one-year anniversary of the grant date and (ii) the Issuer's 2027 Annual Meeting.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 2, 2026 21:47 UTC Swarmer, Inc SWMR · Entity 5442 GrantStock Option (right to buy) · Derivative 6,428 $0.00 Strike: $16.38 $0.00
Disclosure

SEC source: 0001104659-26-113391 · tm2626938-6_4seq1.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,428

Underlying: Common Stock · 6,428 shares

Expires 2036-10-01

F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) the one-year anniversary of the grant date and (ii) the Issuer's 2027 Annual Meeting.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:51 UTC Swarmer, Inc SWMR · Entity 5442 OtherWarrants · Derivative 899,988 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-108626 · tm2625627-2_4seq1.xml · derivative · entry 4

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Theseus Capital Partners, LLC

Disclosed balance after: 0

Underlying: Common Stock · 899,988 shares

Expires not disclosed

F3 · derivative.exercise_price: On September 16, 2026, the Reporting Person, through Theseus, exercised in full all 899,988 Common Stock Purchase Warrants (the "Warrants") held by Theseus pursuant to the cashless exercise provision contained therein (the "Warrant Exercise"). Under the terms of the cashless exercise, no cash consideration was paid to the Issuer. Instead, a portion of the shares of Common Stock otherwise issuable upon exercise of the Warrants was withheld by the Issuer in satisfaction of the aggregate exercise price of $3.3334 per warrant share. Based on a price of $37.2672 per share (the price per share as determined pursuant to the cashless exercise provision of the Warrants), the cashless exercise of all 899,988 Warrants resulted in the issuance to Theseus (or its designee) of 819,487 shares of Common Stock (the "Warrant Shares"), after withholding 80,501 shares in payment of the aggregate exercise price. The Warrant Shares are subject to the beneficial ownership limitation of 4.99%

F4 · derivative.exercise_price: (the "Beneficial Ownership Limitation") set forth in the Warrants, and any Warrant Shares in excess of the Beneficial Ownership Limitation are held in abeyance and will not be issued to the Reporting Person until they are able to be received in accordance with the terms of the Warrants (and thus the Reporting Person does not beneficially own shares held in abeyance). Of the Warrant Shares, 768,971 shares were initially issued to Theseus, and the remaining 50,516 shares were held in abeyance. Subsequent to the initial issuance and prior to the date hereof, the remaining 50,516 shares initially held in abeyance were issued to Theseus following an increase in the number of the Issuer's shares outstanding. The foregoing description of the Warrants and the cashless exercise is qualified in its entirety by the terms and conditions of the Warrants, a form of which was filed as Exhibit 4.3 to the Issuer's Registration Statement on Form S-1/A filed with the SEC on February 19, 2026.

F3 · price: On September 16, 2026, the Reporting Person, through Theseus, exercised in full all 899,988 Common Stock Purchase Warrants (the "Warrants") held by Theseus pursuant to the cashless exercise provision contained therein (the "Warrant Exercise"). Under the terms of the cashless exercise, no cash consideration was paid to the Issuer. Instead, a portion of the shares of Common Stock otherwise issuable upon exercise of the Warrants was withheld by the Issuer in satisfaction of the aggregate exercise price of $3.3334 per warrant share. Based on a price of $37.2672 per share (the price per share as determined pursuant to the cashless exercise provision of the Warrants), the cashless exercise of all 899,988 Warrants resulted in the issuance to Theseus (or its designee) of 819,487 shares of Common Stock (the "Warrant Shares"), after withholding 80,501 shares in payment of the aggregate exercise price. The Warrant Shares are subject to the beneficial ownership limitation of 4.99%

F4 · price: (the "Beneficial Ownership Limitation") set forth in the Warrants, and any Warrant Shares in excess of the Beneficial Ownership Limitation are held in abeyance and will not be issued to the Reporting Person until they are able to be received in accordance with the terms of the Warrants (and thus the Reporting Person does not beneficially own shares held in abeyance). Of the Warrant Shares, 768,971 shares were initially issued to Theseus, and the remaining 50,516 shares were held in abeyance. Subsequent to the initial issuance and prior to the date hereof, the remaining 50,516 shares initially held in abeyance were issued to Theseus following an increase in the number of the Issuer's shares outstanding. The foregoing description of the Warrants and the cashless exercise is qualified in its entirety by the terms and conditions of the Warrants, a form of which was filed as Exhibit 4.3 to the Issuer's Registration Statement on Form S-1/A filed with the SEC on February 19, 2026.

F6 · derivative.exercise_date: The Warrants were immediately exercisable upon the completion of the Issuer's initial public offering.

F7 · derivative.expiration_date: The Warrants will expire upon the earlier of (i) 5:00 p.m. Eastern Time on the 5-year anniversary of the effectiveness of the Issuer's registration statement filed in connection with its initial public offering and (ii) 5:00 p.m. Eastern Time on March 22, 2027.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:51 UTC Swarmer, Inc SWMR · Entity 5442 OtherCommon Stock 819,487 $3.33 $2,731,677.97
Disclosure

SEC source: 0001104659-26-108626 · tm2625627-2_4seq1.xml · nonDerivative · entry 3

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Theseus Capital Partners, LLC

Disclosed balance after: 819,487

F3 · kind: On September 16, 2026, the Reporting Person, through Theseus, exercised in full all 899,988 Common Stock Purchase Warrants (the "Warrants") held by Theseus pursuant to the cashless exercise provision contained therein (the "Warrant Exercise"). Under the terms of the cashless exercise, no cash consideration was paid to the Issuer. Instead, a portion of the shares of Common Stock otherwise issuable upon exercise of the Warrants was withheld by the Issuer in satisfaction of the aggregate exercise price of $3.3334 per warrant share. Based on a price of $37.2672 per share (the price per share as determined pursuant to the cashless exercise provision of the Warrants), the cashless exercise of all 899,988 Warrants resulted in the issuance to Theseus (or its designee) of 819,487 shares of Common Stock (the "Warrant Shares"), after withholding 80,501 shares in payment of the aggregate exercise price. The Warrant Shares are subject to the beneficial ownership limitation of 4.99%

F4 · kind: (the "Beneficial Ownership Limitation") set forth in the Warrants, and any Warrant Shares in excess of the Beneficial Ownership Limitation are held in abeyance and will not be issued to the Reporting Person until they are able to be received in accordance with the terms of the Warrants (and thus the Reporting Person does not beneficially own shares held in abeyance). Of the Warrant Shares, 768,971 shares were initially issued to Theseus, and the remaining 50,516 shares were held in abeyance. Subsequent to the initial issuance and prior to the date hereof, the remaining 50,516 shares initially held in abeyance were issued to Theseus following an increase in the number of the Issuer's shares outstanding. The foregoing description of the Warrants and the cashless exercise is qualified in its entirety by the terms and conditions of the Warrants, a form of which was filed as Exhibit 4.3 to the Issuer's Registration Statement on Form S-1/A filed with the SEC on February 19, 2026.

F5 · kind: In connection with the Warrant Exercise, the Reporting Person entered into a lock-up agreement with the Issuer (the "Lock-Up Agreement") dated as of September 17, 2026, pursuant to which the Reporting Person agreed that all shares of Common Stock received upon exercise of the Warrants (including any shares held in abeyance) are subject to certain transfer restrictions for a six-month period as set forth in the Lock-Up Agreement. The foregoing description of the Lock-Up Agreement is qualified in its entirety by the terms and conditions of the Lock-Up Agreement.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 21:51 UTC Swarmer, Inc SWMR · Entity 5442 OtherCommon Stock 1,124,981 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-108626 · tm2625627-2_4seq1.xml · nonDerivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Theseus Capital Partners, LLC

Disclosed balance after: 0

F1 · kind: Pro rata distribution by Theseus Capital Partners, LLC ("Theseus"). The Reporting Person is the managing member of Theseus and may be deemed to share voting and dispositive power over the shares held by Theseus.

F2 · shares: On September 15, 2026, Theseus made a distribution of 1,124,981 shares of common stock to the members of Theseus on a pro rata basis in accordance with the terms of its Operating Agreement. The disposition reflects the Reporting Person's reduction in beneficial ownership resulting from such distribution.

Read SEC document
August 13, 2026 Filed Aug 17, 2026 20:55 UTC Swarmer, Inc SWMR · Entity 5442 GrantStock Option (right to buy) · Derivative 2,511 $0.00 Strike: $42.99 $0.00
Disclosure

SEC source: 0001104659-26-097922 · tm2623421-4_4seq1.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,511

Underlying: Common Stock · 2,511 shares

Expires 2036-08-13

F1 · derivative.exercise_date: The shares underlying this option vested immediately on the grant date.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:56 UTC Immunome Inc. IMNM · Entity 4219 GrantDirector Stock Option (right to buy) · Derivative 9,897 $0.00 Strike: $18.16 $0.00
Disclosure

SEC source: 0001405684-26-000003 · form4-06122026_090615.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,897

Underlying: Common Stock · 9,897 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Read SEC document
March 23, 2026 Filed Mar 24, 2026 01:23 UTC Immunome Inc. IMNM · Entity 4219 SaleCommon Stock 28,200 $20.65 $582,330.00
Disclosure

SEC source: 0001405684-26-000002 · form4-03242026_010325.xml · nonDerivative · entry 2

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 341,147

F2 · price: The weighted average sale price for the transaction report was $20.65, and the range of prices were between $20.15 and $20.84, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 01:23 UTC Immunome Inc. IMNM · Entity 4219 SaleCommon Stock 36,800 $20.47 $753,296.00
Disclosure

SEC source: 0001405684-26-000002 · form4-03242026_010325.xml · nonDerivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 369,347

F1 · price: The weighted average sale price for the transaction report was $20.47, and the range of prices were between $20.07 and $20.96, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
March 18, 2026 Filed Mar 18, 2026 23:37 UTC Swarmer, Inc SWMR · Entity 5442 ConversionSeries A-1 Preferred Stock · Derivative 597,980 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-031469 · tm268262-12_4seq1.xml · derivative · entry 2

WAGENHEIM PHILIP · CIK 0001405684 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Theseus Capital Partners, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,124,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-1 Preferred Stock converted into shares of common stock on a 1-for-1.8813 basis and had no expiration date.

F1 · price: The Series A-1 Preferred Stock converted into shares of common stock on a 1-for-1.8813 basis and had no expiration date.

F1 · derivative.exercise_date: The Series A-1 Preferred Stock converted into shares of common stock on a 1-for-1.8813 basis and had no expiration date.

F1 · derivative.expiration_date: The Series A-1 Preferred Stock converted into shares of common stock on a 1-for-1.8813 basis and had no expiration date.

F2 · ownership.nature: The shares are directly held by Theseus Capital Partners, LLC ("Theseus"). The Reporting Person is the managing partner of Theseus and may be deemed to share voting and dispositive power over the shares held by Theseus.

Read SEC document
March 18, 2026 Filed Mar 18, 2026 23:37 UTC Swarmer, Inc SWMR · Entity 5442 ConversionCommon Stock 1,124,981 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-031469 · tm268262-12_4seq1.xml · nonDerivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Theseus Capital Partners, LLC

Disclosed balance after: 1,124,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A-1 Preferred Stock converted into shares of common stock on a 1-for-1.8813 basis and had no expiration date.

F2 · ownership.nature: The shares are directly held by Theseus Capital Partners, LLC ("Theseus"). The Reporting Person is the managing partner of Theseus and may be deemed to share voting and dispositive power over the shares held by Theseus.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:55 UTC Immunome Inc. IMNM · Entity 4219 GrantDirector Stock Option (right to buy) · Derivative 18,864 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001415889-25-016987 · form4-06122025_080651.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,864

Underlying: Common Stock · 18,864 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Read SEC document
June 13, 2024 Filed Jun 19, 2024 00:54 UTC Immunome Inc. IMNM · Entity 4219 GrantStock option (right to buy) · Derivative 11,333 $0.00 Strike: $16.04 $0.00
Disclosure

SEC source: 0001415889-24-017520 · form4-06192024_120643.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:48 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $4.84 $0.00
Disclosure

SEC source: 0001104659-23-070395 · tm2318426d2_4seq1.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date.

Read SEC document
January 15, 2023 Filed Jan 17, 2023 11:30 UTC Immunome Inc. IMNM · Entity 4219 GrantCommon Stock 8,750 $4.00 $35,000.00
Disclosure

SEC source: 0001104659-23-004010 · tm233517-4_4seq1.xml · nonDerivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,147

F1 · price: The shares of Common Stock were issued to the Reporting Person pursuant to the Issuer's 2020 Equity Compensation Plan in lieu of the non-employee director board and committee cash retainers of $35,000 in the aggregate owed to the Reporting Person for service on the board of directors in 2022.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 22:04 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001104659-22-073099 · tm2218674-6_4seq1.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date.

Read SEC document
May 28, 2021 Filed Jun 2, 2021 00:06 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 3,750 $0.00 Strike: $20.92 $0.00
Disclosure

SEC source: 0001104659-21-075265 · tm2118079-9_4seq1.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common stock · 3,750 shares

Expires 2031-05-28

F1 · derivative.exercise_date: The shares subject to the option shall vest 25% every quarter after the grant date.

Read SEC document
May 24, 2021 Filed May 27, 2021 01:29 UTC Immunome Inc. IMNM · Entity 4219 PurchaseCommon Stock 13,500 $18.35 $247,725.00
Disclosure

SEC source: 0001104659-21-072619 · tm2117684-3_4seq1.xml · nonDerivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 397,397

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $18.15 to $18.40, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.

F2 · balance_after: Does not include (i) 166,666 shares previously reported as indirectly held by the reporting person because the reporting person is no longer trustee of the Rapoport Family Trust and (ii) 443,743 shares previously reported as held indirectly through BCM Advisory Partners LLC (the "LLC") in which the reporting person did not have a pecuniary interest and which were distributed to other members of the LLC.

Read SEC document
November 03, 2020 Filed Nov 6, 2020 01:17 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy)(1) · Derivative 7,500 $0.00 Strike: $11.38 $0.00
Disclosure

SEC source: 0001104659-20-122035 · a4.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-11-03

F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.